Avantor (NYSE:AVTR) Hits New 12-Month High – Here’s What Happened

Avantor, Inc. (NYSE:AVTR)’s stock price hit a new 52-week high during mid-day trading on Friday. The stock traded as high as $16.45 and last traded at $16.2940, with a volume of 29,355,689 shares. The stock had previously closed at $16.09.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on AVTR shares. TD Cowen raised their price target on shares of Avantor from $15.00 to $17.00 and gave the company a “hold” rating in a research note on Tuesday. Barclays boosted their price objective on shares of Avantor from $13.00 to $15.00 and gave the stock an “underweight” rating in a research note on Wednesday, October 7th. Jefferies Financial Group upgraded Avantor from an “underperform” rating to a “hold” rating and set a $13.00 price objective for the company in a report on Wednesday, July 29th. UBS Group began coverage on Avantor in a research report on Wednesday, September 9th. They set a “neutral” rating and a $16.00 target price for the company. Finally, Royal Bank Of Canada lifted their target price on Avantor from $9.00 to $14.00 and gave the stock a “sector perform” rating in a report on Thursday, July 30th. Two research analysts have rated the stock with a Buy rating, fifteen have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $13.06.

Avantor Price Performance

The business’s fifty day moving average is $14.85 and its 200 day moving average is $11.37. The company has a market cap of $11.02 billion, a P/E ratio of -19.40, a PEG ratio of 8.93 and a beta of 0.94. The company has a current ratio of 1.78, a quick ratio of 1.18 and a debt-to-equity ratio of 0.65.

Avantor (NYSE:AVTR) last issued its quarterly earnings data on Wednesday, July 29th. The company reported $0.21 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.19 by $0.02. The company had revenue of $1.69 billion for the quarter, compared to the consensus estimate of $1.61 billion. Avantor had a positive return on equity of 9.92% and a negative net margin of 8.81%. The firm’s revenue was up .5% compared to the same quarter last year. During the same quarter last year, the business posted $0.24 earnings per share. Avantor has set its FY 2026 guidance at 0.800-0.830 EPS. As a group, sell-side analysts anticipate that Avantor, Inc. will post 0.81 EPS for the current year.

Institutional Trading of Avantor

Hedge funds have recently added to or reduced their stakes in the business. BlackRock Inc. acquired a new stake in shares of Avantor in the 2nd quarter worth $695,784,000. Barrow Hanley Mewhinney & Strauss LLC acquired a new stake in Avantor in the second quarter valued at $195,386,000. Engine Capital Management LP raised its holdings in shares of Avantor by 65.8% during the first quarter. Engine Capital Management LP now owns 19,780,830 shares of the company’s stock worth $155,082,000 after purchasing an additional 7,853,018 shares during the period. Dimensional Fund Advisors LP raised its stake in shares of Avantor by 15.7% during the 1st quarter. Dimensional Fund Advisors LP now owns 16,894,649 shares of the company’s stock worth $132,443,000 after purchasing an additional 2,288,053 shares in the last quarter. Finally, Bank of America Corp DE acquired a new stake in shares of Avantor in the second quarter valued at approximately $108,795,000. 95.08% of the stock is owned by hedge funds and other institutional investors.

Avantor Company Profile

Avantor, Inc is a global provider of products, services and solutions used in the life sciences and advanced technology industries. The company supplies materials and equipment that support research, drug discovery and development, biopharmaceutical manufacturing, clinical and diagnostic activities, and other laboratory applications.

Its offerings include laboratory chemicals and reagents, consumables, single-use manufacturing technologies, bioprocessing products, equipment, and related services.